Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 9;219(4):e20210739. doi: 10.1084/jem.20210739

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Jiang et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 6. — MEK inhibition with FeADC enables dose intensity in combination therapies. (A) Mouse body weight changes normalized to the baseline after the treatment with the vehicle, 30 mg/kg RMC-4550 monotherapy, or combinations comprising 30 mg/kg RMC-4550 combined with COBI at either 7.5 mg/kg or 10 mg/kg or RMC-4550 with comparable (equimolar) 12.5 mg/kg or 16 mg/kg doses of TRX-COBI. Error bars represent mean ± SEM, n = 6 mice/group and analyzed by a two-sample t-test. **, P < 0.01. (B) Tumor volume changes of PDX TM00186 tumors after the treatments in D. Error bars represent mean ± SEM, n = 6 mice/group and analyzed by one-way ANOVA; **, P < 0.01. (C) Western blot for phosphorylated ERK of tumor xenografts and spleen from NSG mice after treatment with vehicle, RMC 30 mg per kg (mpk) + COBI 10 mpk or RMC 30 mpk + TRX-COBI 16 mpk in the cohort of A and B. (D) Quantification of phosphorylated ERK expression in C, error bars represent mean ± SEM, and analyzed by a two-sample t-test. *, P < 0.1; **, P < 0.01.